Evidence map›Paper›PMID 40883565›Full record

ArticleMedical oncology (Northwood, London, England)2025

Wedelolactone induces pyroptosis to suppress retinoblastoma by inhibiting the Nrf2/Keap1 signaling pathway.

Yizhou Jiang, Hua Jiang, Guitao Wu, Ningdong Pang, Chuanqiang Niu, Zhouping Wang, Haibo Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Oxidative Stress andInternational journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yizhou Jiang *Department of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.9, Jinsui road, Tianhe District, Guangzhou, 510627, Guangdong, China.
Hua Jiang *Department of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.9, Jinsui road, Tianhe District, Guangzhou, 510627, Guangdong, China.
Guitao WuDepartment of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.9, Jinsui road, Tianhe District, Guangzhou, 510627, Guangdong, China.
Ningdong PangDepartment of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.9, Jinsui road, Tianhe District, Guangzhou, 510627, Guangdong, China.
Chuanqiang NiuDepartment of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.9, Jinsui road, Tianhe District, Guangzhou, 510627, Guangdong, China.
Zhouping WangDepartment of Pediatric Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China. wang_zhouping@gwcmc.org.
Haibo LiDepartment of Interventional Radiology & Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, No.9, Jinsui road, Tianhe District, Guangzhou, 510627, Guangdong, China.

Funding

Guangzhou Women and Children's Medical Center Doctoral Initiation Fund 2023BS026the Guangzhou Science and Technology Program Project 202201020606
6 · The paper itself

Abstract

backgroundRetinoblastoma is an intraocular malignancy with limited therapeutic options, imposing a severe health burden on young patients. Wedelolactone (WDL), a natural product from E. prostrata, possesses an anti-retinoblastoma activity, with the underlying regulatory mechanism remaining unknown.

methodsRetinoblastoma cell lines and xenograft nude mouse models were treated with WDL and RTA-408, an agonist for nuclear factor-erythroid 2-related factor 2 (Nrf2). Western blotting was conducted to determine the protein expression levels of kelch-like ECH-associated protein 1 (Keap1) and Nrf2. We performed the cell counting kit-8 assay, the 5-ethynyl-2-deoxyuridine staining, and flow cytometry to detect cell viability, proliferation, and apoptosis, respectively. The tumor progression in vivo was evaluated via the measurement of volume, weight, and proliferation levels of solid tumors. Monosodium urate crystal was applied to activate pyroptosis which was assessed by the expression detection of pyroptosis-related indicators.

resultsWDL treatment elevated the expression of Keap1 and reduced the level of Nrf2. RTA-408 suppressed WDL-induced pyroptosis of retinoblastoma cells and reversed the effect of WDL on inhibiting retinoblastoma cell proliferation, promoting tumor cell apoptosis, and repressing the growth of solid tumors of the xenograft models. In addition, monosodium urate-induced pyroptosis partially restored the anti-retinoblastoma effect of WDL impaired by RTA-408.

conclusionWDL triggers pyroptosis by inhibiting the Nrf2/Keap1 signaling pathway to exert anti-retinoblastoma effects.

Indexed as

CoumarinsKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2PyroptosisRetinal NeoplasmsRetinoblastomaAnimalsCell Line, TumorCell ProliferationHumansMiceMice, Inbred BALB CMice, NudeSignal TransductionXenograft Model Antitumor AssaysCoumarinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2wedelolactonePyroptosisRetinoblastomaThe Nrf2/Keap1 signaling pathwayWedelolactone

Identifiers

PMID40883565
PMCPMC12397164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.